便携式呼气挥发性有机化合物监测在SARS-CoV-2 Delta变异株流行及向Omicron变异株过渡期间检测COVID-19
该诊断研究纳入2021年4月至2022年5月密歇根大学健康系统ICU和急诊科167例成人患者、205份呼气样本,用便携式气相色谱分析呼气VOC。4种VOC标志物区分COVID-19(Delta及其他2021年变异株)与非COVID-19疾病的准确率为94.7%,但用于Omicron变异株时准确率降至82.1%;4种新VOC标志物区分Omicron与非COVID-19的准确率为90.9%。呼气分析区分Omicron与早期变异株的准确率为91.5%,区分COVID-19(所有SARS-CoV-2变异株)与非COVID-19的准确率为90.2%。作者认为呼气分析有检测COVID-19的前景,但新变异株出现带来诊断挑战,类似快速抗原检测,需进一步评估如何克服这些挑战。
要点
- 4种VOC标志物区分COVID-19(Delta及其他2021年变异株)与非COVID-19疾病的准确率为94.7%。
- 同一组4种VOC标志物用于Omicron变异株时准确率降至82.1%。
- 4种新VOC标志物区分Omicron与非COVID-19疾病的准确率为90.9%。
- 呼气分析区分Omicron与早期变异株的准确率为91.5%,区分COVID-19(所有SARS-CoV-2变异株)与非COVID-19的准确率为90.2%。
- 作者认为呼气分析有检测COVID-19的前景,但新变异株出现带来诊断挑战,类似快速抗原检测,需进一步评估如何克服这些挑战。
适用人群与场景
- 2021年4月至2022年5月经逆转录聚合酶链反应检测COVID-19阳性及阴性的成人患者,通过密歇根大学健康系统的ICU和急诊科入组。
- 共分析167例成人患者的205份呼气样本;77例COVID-19患者(平均[SD]年龄58.5[16.1]岁;41例[53.2%]男性;13例[16.9%]黑人、59例[76.6%]白人),91例非COVID-19疾病患者(平均[SD]年龄54.3[17.1]岁;43例[47.3%]男性;11例[12.1%]黑人、76例[83.5%]白人)。
- 部分患者多日重复分析;94份阳性样本中41份来自2021年感染Delta或其他变异株的患者,53份来自2022年感染Omicron变异株的患者(依据密歇根州和美国疾病控制与预防中心监测数据)。
研究设计与关键结果
- 研究类型为诊断研究,纳入167例成人患者、205份呼气样本,通过ICU和急诊科入组,用便携式气相色谱分析呼气。
- 4种VOC标志物区分COVID-19(Delta及其他2021年变异株)与非COVID-19疾病的准确率为94.7%。
- 同一组标志物用于Omicron变异株时准确率降至82.1%。
- 4种新VOC标志物区分Omicron变异株与非COVID-19疾病的准确率为90.9%。
- 呼气分析区分Omicron与早期变异株的准确率为91.5%,区分COVID-19(所有SARS-CoV-2变异株)与非COVID-19疾病的准确率为90.2%。
证据类型、等级与局限
- 证据类型:诊断研究。
- 作者指出,与快速抗原检测类似,新变异株的出现带来诊断挑战。
- 作者指出,本研究结果需进一步评估如何克服这些挑战,以利用呼气分析改善患者诊断和护理。
对床旁实践的改变
- 作者认为呼气分析有检测COVID-19的前景,但新变异株出现带来诊断挑战,类似快速抗原检测。
- 作者指出,本研究结果需进一步评估如何克服这些挑战,以利用呼气分析改善患者诊断和护理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Breath analysis has been explored as a noninvasive means to detect COVID-19. However, the impact of emerging variants of SARS-CoV-2, such as Omicron, on the exhaled breath profile and diagnostic accuracy of breath analysis is unknown.
OBJECTIVE: To evaluate the diagnostic accuracies of breath analysis on detecting patients with COVID-19 when the SARS-CoV-2 Delta and Omicron variants were most prevalent.
DESIGN, SETTING, AND PARTICIPANTS: This diagnostic study included a cohort of patients who had positive and negative test results for COVID-19 using reverse transcriptase polymerase chain reaction between April 2021 and May 2022, which covers the period when the Delta variant was overtaken by Omicron as the major variant. Patients were enrolled through intensive care units and the emergency department at the University of Michigan Health System. Patient breath was analyzed with portable gas chromatography.
MAIN OUTCOMES AND MEASURES: Different sets of VOC biomarkers were identified that distinguished between COVID-19 (SARS-CoV-2 Delta and Omicron variants) and non-COVID-19 illness.
RESULTS: Overall, 205 breath samples from 167 adult patients were analyzed. A total of 77 patients (mean [SD] age, 58.5 [16.1] years; 41 [53.2%] male patients; 13 [16.9%] Black and 59 [76.6%] White patients) had COVID-19, and 91 patients (mean [SD] age, 54.3 [17.1] years; 43 [47.3%] male patients; 11 [12.1%] Black and 76 [83.5%] White patients) had non-COVID-19 illness. Several patients were analyzed over multiple days. Among 94 positive samples, 41 samples were from patients in 2021 infected with the Delta or other variants, and 53 samples were from patients in 2022 infected with the Omicron variant, based on the State of Michigan and US Centers for Disease Control and Prevention surveillance data. Four VOC biomarkers were found to distinguish between COVID-19 (Delta and other 2021 variants) and non-COVID-19 illness with an accuracy of 94.7%. However, accuracy dropped substantially to 82.1% when these biomarkers were applied to the Omicron variant. Four new VOC biomarkers were found to distinguish the Omicron variant and non-COVID-19 illness (accuracy, 90.9%). Breath analysis distinguished Omicron from the earlier variants with an accuracy of 91.5% and COVID-19 (all SARS-CoV-2 variants) vs non-COVID-19 illness with 90.2% accuracy.
CONCLUSIONS AND RELEVANCE: The findings of this diagnostic study suggest that breath analysis has promise for COVID-19 detection. However, similar to rapid antigen testing, the emergence of new variants poses diagnostic challenges. The results of this study warrant additional evaluation on how to overcome these challenges to use breath analysis to improve the diagnosis and care of patients.
参考来源
- Sharma R, Zang W, Tabartehfarahani A, et al. Portable Breath-Based Volatile Organic Compound Monitoring for the Detection of COVID-19 During the Circulation of the SARS-CoV-2 Delta Variant and the Transition to the SARS-CoV-2 Omicron Variant. JAMA Netw Open. 2023. PMID: 36853606. doi:10.1001/jamanetworkopen.2023.0982
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。